Drug Shortage Report for POTASSIUM PHOSPHATES INJECTION, USP
| Report ID | 240890 |
| Drug Identification Number | 02139545 |
| Brand name | POTASSIUM PHOSPHATES INJECTION, USP |
| Common or Proper name | POTASSIUM PHOSPHATES INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
| Strength(s) | 236MG 224MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 50 mL |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-11-01 |
| Actual start date | |
| Estimated end date | 2024-12-02 |
| Actual end date | 2024-12-02 |
| Shortage status | Actual shortage |
| Updated date | 2024-12-02 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Potassium Phosphates Injection, USP 3 mmol/mL Phosphorus SD Vial 50 mL effective November 1, 2024 until December 2, 2024. Baxter is an alternate supplier of Potassium Phosphates Injection and have been informed of our impending supply interruption. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2024-12-02 | French | Compare |
| v4 | 2024-12-02 | English | Compare |
| v3 | 2024-11-02 | English | Compare |
| v2 | 2024-10-22 | French | Compare |
| v1 | 2024-10-22 | English | Compare |
Showing 1 to 5 of 5